| Literature DB >> 33145204 |
Deepak Khatri1, Kuntal Kanti Das2, Jaskaran Singh Gosal2, Gagandeep Attri2, Amanjot Singh2, Kamlesh Singh Bhaisora2, Anant Mehrotra2, Jayesh Sardhara2, Pawan Kumar Verma2, Arun Kumar Srivastava2, Awadhesh Kumar Jaiswal2, Sanjay Behari2.
Abstract
BACKGROUND: Insular high-grade gliomas are uncommon and constitute approximately 10% of all intracranial high-grade gliomas. Several publications in the recent years have thrown substantial light in the understanding of insular low-grade gliomas. However, there is a paucity of information concerning the spectrum of high-grade lesions affecting the insula, the mode of presentation vis-à-vis low-grade gliomas, and the survival rates to modern therapy. AIMS ANDEntities:
Keywords: Factors; glioblastoma; high-grade glioma; insular lobe; outcome; surgery; survival
Year: 2020 PMID: 33145204 PMCID: PMC7591198 DOI: 10.4103/ajns.AJNS_18_20
Source DB: PubMed Journal: Asian J Neurosurg
Demographic details and modes of clinical presentation of our patient group
| Description | Number of patients ( |
|---|---|
| Demographics | |
| Mean age±SD (years) | 41.27±15.36 |
| Median age (range) | 40 (4-72) |
| Gender | |
| Male | 33 (80.5) |
| Female | 8 (19.5) |
| Mean duration of presenting symptoms (months) | 7.06±10.96 |
| Follow up duration (months), mean±SD | 18.39±23.44 |
| Clinical presentation | |
| Sensorium | |
| Conscious, oriented | 27 (65.9) |
| Disoriented | 12 (29.3) |
| Unable to follow commands | 2 (4.9) |
| Features of raised ICP | |
| Headache | 28 (68.3) |
| Vomiting | 10 (24.4) |
| Papilledema | 19 (46.3) |
| FND | |
| Motor deficits | 17 (41.5) |
| Speech involvement | 1 (2.4) |
| Both | 7 (17.1) |
| Seizures | 24 (58.5) |
| Focal aware | 10 (24.4) |
| Focal with impaired awareness | 10 (24.4) |
| Generalized | 4 (9.8) |
| Others | |
| Impaired memory | 6 (14.6) |
| Altered behaviour | 6 (14.6) |
SD – Standard deviation; ICP – Intracranial pressure; FND – Focal neurological deficits
A summary of various radiological parameters of in our study
| Description | Number of patients ( |
|---|---|
| Radiological parameters | |
| Laterality | |
| Right | 17 (41.5) |
| Left | 24 (58.5) |
| Tumor size (cm) | |
| More than 4 | 33 (80.5) |
| <4 | 8 (19.5) |
| MCA shift | 19 (46.3) |
| Exophytic component | 3 (7.3) |
| Location (as per BS zones) | |
| I + II | 2 (4.9) |
| II + III | 2 (4.9) |
| I + II + III | 5 (12.2) |
| II + III + IV | 7 (17.1) |
| All | 25 (61) |
| Yasargil’s classification | |
| 3A | 1 (2.4) |
| 3B | 9 (22) |
| 5A | 11 (26.8) |
| 5B | 20 (48.8) |
| Contrast enhancement | |
| Homogeneous | 3 (7.3) |
| Heterogenous | 25 (61) |
| No enhancement | 13 (31.7) |
MCA – Middle cerebral artery; BS: Berger-sanai
Operative details and histopathological distribution of our cases
| Description | Number of patients ( |
|---|---|
| Operative details | |
| Anesthesia | |
| GA | 39 (95.1) |
| Awake | 2 (4.9) |
| Approach | |
| Transopercular | 28 (68.3) |
| Transylvian | 13 (31.7) |
| EOR | |
| Near total | 23 (56.1) |
| Subtotal | 18 (43.9) |
| Other | |
| Lobectomy (yes/no) | 28/13 |
| Resurgery | 14 (34.1) |
| WHO grade | |
| Grade III | 20 (48.8) |
| AA | 15 |
| AOA | 4 |
| AODG | 1 |
| Grade IV | 21 (51.2) |
| GBM | 15 |
| GS | 3 |
| PNET | 2 |
| ATRT | 1 |
| Adjuvant therapy | |
| Radiotherapy | 28 (68.3) |
| Chemotherapy | 28 (68.3) |
GA – General anesthesia; EOR – Extent of resection; AA – Anaplastic astrocytoma; AOA – Anaplastic oligoastrocytoma; AODG – Anaplastic oligodendroglioma; GBM – Glioblastoma; GS – Gliosarcoma; PNET – Primitive neuroectodermal tumor; ATRT – Atypical teratoid rhabdoid tumor
A summary of various clinical outcome parameters in our study
| Description | Number of patients ( |
|---|---|
| Functional status | |
| Preoperative KPS, median (range) | 80 (20-90) |
| KPS at discharge, median (range) | 80 (30-90) |
| Seizure outcome | |
| Engel grade | |
| 1A | 33 (80.5) |
| 1C | 2 (4.9) |
| 2B | 3 (7.3) |
| 2C | 1 (2.4) |
| ILAE grade | |
| 1A | 33 (80.5) |
| 3 | 6 (14.6) |
| Antiepileptic drugs | |
| Monotherapy | 24 (58.5) |
| Two or more AEDs | 17 (41.5) |
| Survival outcome | |
| Survived | 14 (34.1) |
| Died | 25 (61) |
| Within 3 months | 14 (56) |
| 3-6 months | 3 (12) |
| Beyond 6 months | 8 (32) |
| Lost to follow-up | 2 (4.9) |
KPS – Karnofsky’s performance score; AED – Antiepileptic drugs
Chart 1Kaplan–Meier survival curves comparing the overall survival between Grade 3 and Grade 4 tumors
Chart 2A comparative analysis of progression-free survival between Grade 3 and Grade 4 tumors